To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in Solid Tumors

Conditions:   Bone Sarcoma;   Soft Tissue Sarcoma;   Melanoma;   Liver Cancer;   Esophageal Cancer;   Breast Cancer;   Thyroid Cancer;   Ovarian Cancer
Interventions:   Drug: Cyclophosphamide;   Biological: TAEST16001
Sponsors:   Zhujiang Hospital;   Xiangxue Life Science Research Center;   Guangdong Xiangxue Precision Medical Technology Co., Ltd;   Guangzhou Xiangxue Pharmaceutical Co., Ltd
Recruiting - verified May 2017

http://ift.tt/2ruRjA2